NIH-funded research R01 grant

Understanding how bacteria contribute to gum disease

Official title: Pathoadaptive Modulation of Porphyromonas gingivalis Lipopolysaccharide Structure and Function

Funded at University of Louisville · NIH-10857668 · Data updated 2026-11-12

This study is looking at how certain parts of bacteria might cause gum disease and how a specific molecule helps control these parts, with the hope that it will lead to better treatments for people suffering from periodontitis.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Louisville
NIH-funded
Lab location1 site (Louisville, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2029
Funding year2024
Award (this year)$422,550
NIH project number1R01DE033702-01
Project IDNIH-10857668 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are adults suffering from chronic periodontitis.

Less likely to help

Patients without chronic periodontitis or those under 21 years old may not benefit from this research.

What this research studies

This research investigates the role of specific bacterial components in the development of periodontitis, a common inflammatory disease affecting the tissues that support teeth. The study focuses on how the structure and function of lipopolysaccharides from the bacteria Porphyromonas gingivalis are regulated by a signaling molecule called c-di-AMP. By analyzing the genetic and molecular mechanisms involved, the research aims to uncover how these interactions contribute to the progression of gum disease. Patients may benefit from insights that could lead to new treatments or preventive strategies for periodontitis.

Why it matters

Potential benefit: If successful, this research could lead to improved treatments for periodontitis, potentially reducing tooth loss and improving oral health.

How similar studies have gone: Previous research has shown promising results in understanding bacterial interactions in periodontal diseases, suggesting that this approach could yield valuable insights.

Where this research is happening

  • University of Louisville
    Louisville, United States
    Active

Researchers

  • Principal investigator: Moradali, Fata — University of Louisville
  • Study coordinator: Moradali, Fata

Related research

Other NIH-funded projects on the same topics.

  • Gastric rhythm map to understand stomach problems using a new noninvasive tool

    A new noninvasive body surface mapping method is being tested to see if abnormal stomach electrical rhythms explain chronic stomach problems like functional dyspepsia and persistent nausea.

    NIH research University of Louisville · Louisville, United States · NIH-11611507

  • Novel antivirals for alphavirus arthritis

    A research team is refining a promising antiviral compound to treat alphavirus infections that cause arthritis, with a focus on Chikungunya and related viruses.

    NIH research University of Louisville · Louisville, United States · NIH-11609180

  • Linking heavy metal exposure to a tougher breast cancer type (TNBC)

    Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

    NIH research University of Louisville · Louisville, United States · NIH-11567535

  • Cardiac safety of flavored e-cigarette aerosols in adults

    A pharmacist or clinician would test how inhaling flavored e-cigarette aerosols affects heart rhythm in adults to see if flavors raise the risk of heart problems.

    NIH research University of Louisville · Louisville, United States · NIH-11541950

  • Biomedical Research Facilities to Expand Precision Medicine in Kentucky

    A large NIH grant aims to renovate and expand a shared precision medicine center in Kentucky to speed up research that could improve health for people in Appalachia and surrounding areas.

    NIH research University of Louisville · Louisville, United States · NIH-11523167

  • Rac-enhanced CAR-Macrophages against TNBC

    A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

    NIH research University of Louisville · Louisville, United States · NIH-11520503

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.